A Multicenter, placebo-controlled single blind, dose-escalation, Investigator initiated trial for seven days repeated intravenous administration of NK-104-NP to healthy adult male volunteers for seven days
Latest Information Update: 25 Oct 2018
At a glance
- Drugs Pitavastatin (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Pharmacokinetics
- 26 Sep 2018 Results published in the International Heart Journal
- 16 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan.
- 06 Oct 2015 New trial record